Not All Biomarkers Are The Same

Every Man with Prostate Cancer
DESERVES A BETTER ANSWER

Not all biomarker tests are the same. When it comes to making active surveillance or definitive treatment decisions, selecting the correct biomarker test matters. The Prolaris® test from Myriad Genetics is the only biomarker test on the market with both an Active Surveillance Threshold and a Multi-Treatment Modality Threshold.

Endpoints Matter when Selecting a Biomarker

It is critical to understand what information you are getting when selecting a biomarker. The Prolaris test looks at the disease endpoints that matter most and has been rigorously studied and proven to meet ALL of its primary endpoints.

Prolaris Endpoints:

10-year disease-specific mortality when considering conservative management

10-year risk of developing metastasis when considering definitive treatment

Ready to Learn More?